Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MTRX1011A in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. SAD Stage~   * RA diagnosed according to the ACR~  * For patients taking anti-rheumatic therapies, receipt of a stable regimen prior to randomization~  * Previous treatment with biologic agents, including anti-TNF agents, permitted but discontinued for an appropriate washout period~2. MAD Stage (same as above with the addition of the following)~   * Failure of at least one biologic agent, defined as lack of or loss of response or intolerance~  * Active disease defined by swollen and tender count~Exclusion Criteria:~* Significant systemic involvement of RA, including vasculitis, pulmonary fibrosis, or Felty's syndrome~* Malignancy, or prior malignancy, other than non-melanoma skin cancer or cervical carcinoma in situ that has been resected~* History of treatment with any T cell-directed therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).